Skip to content

Checked

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

NCT07502508 on ClinicalTrials.gov

Study listings come from ClinicalTrials.gov, where sponsors register and update their own studies. A listing does not mean a study is safe or effective, and DatenUS does not recommend any study. Talk with your doctor before joining a clinical trial, and use ClinicalTrials.gov for contact details and full eligibility rules.

Status
Recruiting
Phase
Phase 2
Interventional
Planned enrollment
60
Participants, all sites
U.S. sites
20
In 9 states

Study details

Conditions
Type 2 Diabetes
Sponsor
Biomea Fusion Inc. (Industry)
Ages
18 to 75 years
Sex
All
Healthy volunteers
Not accepted
Start
04/30/2026
Primary completion (expected)
June 2027
Last updated by sponsor
10/20/2026

Full eligibility rules, contacts and site names: NCT07502508 on ClinicalTrials.gov

Where the study has sites

Cities with at least one listed U.S. site. Some sites may not be enrolling yet.

  • Alabama: Birmingham
  • California: Canoga Park, Long Beach, Montclair, San Diego
  • Florida: Fort Myers, Miami Lakes, Winter Park
  • Georgia: Columbus, Cordele
  • Nevada: Las Vegas
  • North Carolina: Morehead City
  • Ohio: Canton
  • Texas: Austin, Dallas, Houston, Lewisville, Missouri City, San Antonio
  • Virginia: Burke

More studies on the same topic

Frequently asked questions

What does recruiting mean?
Recruiting means the study is currently enrolling participants. Not yet recruiting means it has been registered but has not started enrolling. Enrolling by invitation means participants are selected by the study team rather than through open enrollment.
How do I join a clinical trial?
Read the full eligibility criteria and contact information on ClinicalTrials.gov, then talk with your doctor about whether a study may be right for you. The study team decides who can enroll.

Source: ClinicalTrials.gov, National Library of Medicine · Last updated 10/20/2026